Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study
ABSTRACT Background Prostate cancer (PC) patients resistant to castration have decreased survival. Analysis of patient characteristics and disease management can contribute to new strategies to prevent or delay progression to castrate‐resistant prostate cancer (CRPC). This study aimed to characteriz...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221898145103872 |
|---|---|
| author | Pedro Costa António Patrício João Vasco Barreira Luís Abranches Monteiro Luís Campos Pinheiro Paulo Azinhais Inês Sequeira Carlos Rabaça Ferdinando Pereira Ricardo Borges Francisco Botelho Frederico Reis José Carvalho António Canelas Hugo Coelho Fernando Vila Rui Dinis Sílvia Dias Ana Cristina Fialho José Palma dos Reis |
| author_facet | Pedro Costa António Patrício João Vasco Barreira Luís Abranches Monteiro Luís Campos Pinheiro Paulo Azinhais Inês Sequeira Carlos Rabaça Ferdinando Pereira Ricardo Borges Francisco Botelho Frederico Reis José Carvalho António Canelas Hugo Coelho Fernando Vila Rui Dinis Sílvia Dias Ana Cristina Fialho José Palma dos Reis |
| author_sort | Pedro Costa |
| collection | DOAJ |
| description | ABSTRACT Background Prostate cancer (PC) patients resistant to castration have decreased survival. Analysis of patient characteristics and disease management can contribute to new strategies to prevent or delay progression to castrate‐resistant prostate cancer (CRPC). This study aimed to characterize and compare PC patients from initial PC diagnosis to metastatic CRPC (mCRPC) versus nonmetastatic (nmCRPC) stages in a real‐world setting in Portugal. Methods A multicenter, retrospective, non‐interventional study was conducted across 18 Portuguese sites. Consenting adult patients (age ≥ 18 years) diagnosed with CRPC, either metastatic or nonmetastatic, were included in the study at the time of diagnosis or within 12 months of CRPC diagnosis. Results Between November 2020 and December 2022, a total of 121 patients (73 mCRPC patients and 48 nmCRPC patients) were included. At diagnosis, the median age was 69.0 and 70.0 years in mCRPC and nmCRPC patients, respectively, and the most common histological subtype was acinar adenocarcinoma (mCRPC: 83.6%; nmCRPC: 91.7%). Significant differences were observed between the two groups regarding Eastern Cooperative Oncology Group Performance status (ECOG PS) (p = 0.023), Gleason score (p = 0.001), and American Joint Committee on Cancer (AJCC) stage (p < 0.001). The median time from PC diagnosis to first treatment and the treatments used prior to CRPC diagnosis were comparable between the groups. However, the median time from PC diagnosis to CRPC was significantly shorter in mCRPC versus nmCRPC patients (42.0 vs. 58.0 months, p = 0.006). Prostate‐specific antigen (PSA) values were significantly higher in mCRPC than in nmCRPC patients at CRPC diagnosis (19.8 vs. 6.3 ng/mL; p < 0.001). Conclusions This real‐world study showed that the time from initial PC diagnosis to castration resistance was significantly longer in nmCRPC than in mCRPC patients. The characteristics associated with a better prognosis at initial diagnosis and a better treatment response in nmCRPC patients might explain this difference in disease progression. |
| format | Article |
| id | doaj-art-132d001aa4224fafb4a72e8ea492274a |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-132d001aa4224fafb4a72e8ea492274a2025-08-26T10:58:44ZengWileyCancer Medicine2045-76342025-08-011416n/an/a10.1002/cam4.71149Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA StudyPedro Costa0António Patrício1João Vasco Barreira2Luís Abranches Monteiro3Luís Campos Pinheiro4Paulo Azinhais5Inês Sequeira6Carlos Rabaça7Ferdinando Pereira8Ricardo Borges9Francisco Botelho10Frederico Reis11José Carvalho12António Canelas13Hugo Coelho14Fernando Vila15Rui Dinis16Sílvia Dias17Ana Cristina Fialho18José Palma dos Reis19Urology Department Vila Nova de Gaia Hospital Center Vila Nova de Gaia PortugalUrology Department Baixo Vouga Hospital Center Aveiro PortugalOncology Department SAMS Lisbon Lisbon PortugalUrology Department Western Lisbon Hospital Center Lisbon PortugalUrology Department University Hospital Center of Central Lisbon Lisbon PortugalUrology Department Centro Hospitalar e Universitário de Coimbra Coimbra PortugalOncology Department ULS Guarda Guarda PortugalUrology Department Instituto Português de Oncologia de Coimbra Francisco Gentil (IPO) Coimbra PortugalUrology Department SESARAM Funchal PortugalUrology Department Leiria Hospital Center Leiria PortugalUrology Department Centro Hospitalar de São João Oporto PortugalUrology Department ULS Matosinhos Matosinhos PortugalUrology Department Garcia da Orta Hospital Almada PortugalUrology Department Setúbal Hospital Center Setúbal PortugalUrology Department ULS Alto Minho – Viana do Castelo Viana do Castelo PortugalUrology Department Tâmega and Sousa Hospital Center Guilhufe PortugalOncology Department Hospital Do Espírito Santo de Évora Évora PortugalMedical Department Janssen‐Cilag Farmacêutica, LDA Porto Salvo PortugalMedical Department Janssen‐Cilag Farmacêutica, LDA Porto Salvo PortugalUrology Department Santa Maria Hospital Lisbon PortugalABSTRACT Background Prostate cancer (PC) patients resistant to castration have decreased survival. Analysis of patient characteristics and disease management can contribute to new strategies to prevent or delay progression to castrate‐resistant prostate cancer (CRPC). This study aimed to characterize and compare PC patients from initial PC diagnosis to metastatic CRPC (mCRPC) versus nonmetastatic (nmCRPC) stages in a real‐world setting in Portugal. Methods A multicenter, retrospective, non‐interventional study was conducted across 18 Portuguese sites. Consenting adult patients (age ≥ 18 years) diagnosed with CRPC, either metastatic or nonmetastatic, were included in the study at the time of diagnosis or within 12 months of CRPC diagnosis. Results Between November 2020 and December 2022, a total of 121 patients (73 mCRPC patients and 48 nmCRPC patients) were included. At diagnosis, the median age was 69.0 and 70.0 years in mCRPC and nmCRPC patients, respectively, and the most common histological subtype was acinar adenocarcinoma (mCRPC: 83.6%; nmCRPC: 91.7%). Significant differences were observed between the two groups regarding Eastern Cooperative Oncology Group Performance status (ECOG PS) (p = 0.023), Gleason score (p = 0.001), and American Joint Committee on Cancer (AJCC) stage (p < 0.001). The median time from PC diagnosis to first treatment and the treatments used prior to CRPC diagnosis were comparable between the groups. However, the median time from PC diagnosis to CRPC was significantly shorter in mCRPC versus nmCRPC patients (42.0 vs. 58.0 months, p = 0.006). Prostate‐specific antigen (PSA) values were significantly higher in mCRPC than in nmCRPC patients at CRPC diagnosis (19.8 vs. 6.3 ng/mL; p < 0.001). Conclusions This real‐world study showed that the time from initial PC diagnosis to castration resistance was significantly longer in nmCRPC than in mCRPC patients. The characteristics associated with a better prognosis at initial diagnosis and a better treatment response in nmCRPC patients might explain this difference in disease progression.https://doi.org/10.1002/cam4.71149castrate‐resistant prostate cancerdisease managementprostate cancerreal‐world evidencetime to disease progression |
| spellingShingle | Pedro Costa António Patrício João Vasco Barreira Luís Abranches Monteiro Luís Campos Pinheiro Paulo Azinhais Inês Sequeira Carlos Rabaça Ferdinando Pereira Ricardo Borges Francisco Botelho Frederico Reis José Carvalho António Canelas Hugo Coelho Fernando Vila Rui Dinis Sílvia Dias Ana Cristina Fialho José Palma dos Reis Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study Cancer Medicine castrate‐resistant prostate cancer disease management prostate cancer real‐world evidence time to disease progression |
| title | Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study |
| title_full | Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study |
| title_fullStr | Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study |
| title_full_unstemmed | Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study |
| title_short | Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study |
| title_sort | comparison of disease progression from prostate cancer diagnosis to metastatic or nonmetastatic castrate resistant prostate cancer crpc patients capa study |
| topic | castrate‐resistant prostate cancer disease management prostate cancer real‐world evidence time to disease progression |
| url | https://doi.org/10.1002/cam4.71149 |
| work_keys_str_mv | AT pedrocosta comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT antoniopatricio comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT joaovascobarreira comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT luisabranchesmonteiro comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT luiscampospinheiro comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT pauloazinhais comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT inessequeira comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT carlosrabaca comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT ferdinandopereira comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT ricardoborges comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT franciscobotelho comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT fredericoreis comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT josecarvalho comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT antoniocanelas comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT hugocoelho comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT fernandovila comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT ruidinis comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT silviadias comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT anacristinafialho comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy AT josepalmadosreis comparisonofdiseaseprogressionfromprostatecancerdiagnosistometastaticornonmetastaticcastrateresistantprostatecancercrpcpatientscapastudy |